Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0026-0495(69)90141-3 | DOI Listing |
J Vasc Access
January 2025
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
Background: Central venous access devices (CVAD) are widely used in patient care, providing an essential, reliable pathway for patients to receive chemotherapy, long-term infusions, and nutritional support. However, a system of exercise management has not been developed in patients with CVAD.
Purpose: To evaluate and summarize the evidence for management exercise in patients with CVAD and provide guidance for clinical practice.
Front Public Health
January 2025
Department of Health Care Management, School of Information and Management, Guangxi Medical University, Nanning, Guangxi, China.
Background: The aging population presents a significant public health challenge, particularly concerning mental health and injury prevention. Anxiety and depression are common among the older adult, affecting their quality of life and increasing the risk of unintentional injuries (UI). This study aims to explore the association between anxiety and depression and UI risk among the older adult in Guangxi, China, using data from the 2023 National Health Service Survey.
View Article and Find Full Text PDFInt J Clin Health Psychol
January 2025
Department of Psychology and Neurosciences, Leibniz Research Centre for Working Environment and Human Factors, Dortmund, Germany.
Fear extinction is the foundation of exposure therapy for anxiety and phobias. However, the stability of extinction memory diminishes over time, coinciding with fear recovery. To augment long-term extinction retention, the temporal distribution of extinction learning sessions is critical.
View Article and Find Full Text PDFFront Physiol
January 2025
College of Dental Medicine, Lincoln Memorial University, Harrogate, TN, United States.
World J Gastroenterol
January 2025
School of Health Sciences, Universidad Internacional de La Rioja, Logroño 26006, La Rioja, Spain.
This article comments on the work by Soresi and Giannitrapani. The authors have stated that one of the most novel and promising treatments for metabolic dysfunction-associated steatotic liver disease (MASLD) is the use of glucagon-like peptide 1 receptor agonists, especially when used in combination therapy. However, despite their notable efficacy, these drugs were not initially designed to target MASLD directly.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!